Apogee Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Apogee Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2022 to Q3 2024.
  • Apogee Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$49M, a 135% decline year-over-year.
  • Apogee Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$147M, a 121% decline year-over-year.
  • Apogee Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$84M, a 111% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$147M -$49M -$28.2M -135% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$118M -$33.8M -$14.9M -79.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$104M -$32.1M -$19.6M -156% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$84M -$31.7M -$17.7M -127% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$66.3M -$20.8M -$1.18M -6.02% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$65.1M -$18.9M -$17.1M -940% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$48M -$12.5M -$8.22M -191% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$39.8M -$14M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$19.7M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$1.82M Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$4.31M Feb 4, 2022 Mar 31, 2022 10-Q 2023-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.